The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

Detailed price information for Integer Holdings Corp (ITGR-N) from The Globe and Mail including charting and trades.

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

The diabetes tech firm tailored its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin. The device is similar to existing prescription CGMs. Users pair the ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The FDA approves ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

Earlier this year, while speaking with Fierce Medtech at the annual J.P. Morgan Healthcare Conference, Dexcom CEO Kevin Sayer noted that the continuous glucose monitor maker had recently changed its ...

Dexcom, a maker of wearable continuous glucose monitors for people with diabetes, said Thursday that is launching its first corporate venture capital fund to invest in sensing, data analytics, remote ...